Literature DB >> 29964362

Evaluation of the Effects of Apatinib on the Pharmacokinetics of Venlafaxine and O-desmethylvenlafaxine in SD Male Rats by UPLC-MS/MS.

Su-Su Bao1, Jian Wen1, Qian-Meng Lin1, Ying-Hui Li1, Yang-Ge Huang1, Hong-Yu Zhou1, Guo-Xin Hu1.   

Abstract

The objective of this study was to evaluate the effect of apatinib on the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in SD rats and the inhibitory effects of apatinib on venlafaxine in rat and human liver microsomes. Twenty-one SD male rats were randomly divided into three groups (n = 7): group A (multiple dose of 40 mg/kg apatinib for 7 days), group B (single dose of 40 mg/kg apatinib) and group C (the control group). All samples were measured by UPLC-MS/MS. The results indicated that a single dose of apatinib increased the AUC(0-t) , AUC(0-∞) and Cmax of both venlafaxine and O-desmethylvenlafaxine significantly, while Vz/F and CLz/F were decreased. As for group A, only AUC(0-t) and CLz/F of venlafaxine were changed, while no parameters of O-desmethylvenlafaxine were altered. In addition, apatinib was determined to be a mixed inhibitor of venlafaxine.
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29964362     DOI: 10.1111/bcpt.13081

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  2 in total

1.  Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension.

Authors:  Caie Li; Liping Ma; Qiongying Wang; Xuejiao Shao; Lu Guo; Jianshu Chen; Wenjuan Wang; Jing Yu
Journal:  J Hypertens       Date:  2022-04-01       Impact factor: 4.776

2.  CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine.

Authors:  Zhize Ye; Bingbing Chen; Nanyong Gao; Qihui Kong; Xiaoqin Hu; Zhongqiu Lu; Jianchang Qian; Guoxin Hu; Jianping Cai; Bin Wu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.